CKLS 202
Alternative Names: CKLS-202; PDL1-PRAME dual antigen cancer vaccineLatest Information Update: 04 Jul 2025
At a glance
- Originator CK Life Sciences
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma